Despite rising consumer confidence, a lot of factors are plaguing the U.S. economy of late. We note that the market is currently caught between weaker-than-expected March employment data, President Donald Trump’s airstrike against Syria and new policies from Federal Reserve (‘Fed’) that have already begun to hurt investors’ sentiment.
Treasury yields fell Wednesday after the minutes from the Federal Reserve policy-making panels meeting earlier this month showed policy makers largely agreed on the notion of moving to begin shrinking the central banks balance sheet later this year.
Investors and the public still seem to be enthralled by Warren Buffett and Berkshire Hathaway Inc. (NYSE: BRK-A). Many of those same people still know Bill Gates as well. Many people forget about the close ties between the two billionaires. A filing with the Securities andExchange Commission (SEC) on Monday should only serve to remind how deep the ties between Gates and Buffett go.
A strategic mistake made six years ago by celebrity CEO Ron Johnson continues to haunt popular retailer JC Penney, as evidenced by the ongoing sluggish sales growth and store closings that have made the company smaller—a fraction of what it once was.
Meanwhile, investors have been bailing out from the company’s stock,....More>>>
Accenture (NYSE:ACN) is a global technology consulting company that has been in the news a lot over the last month. On March 23, 2017, the company released its Q2 2017 results and revised full-year 2017 guidance, which were widely viewed as “disappointments” by the financial community. In April 2017, there were rumors that Oracle (NYSE:ORCL) was interested in acquiring the company....More>>>
Accenture (NYSE:ACN) is a global technology consulting company that has been in the news a lot over the last month. On March 23, 2017, the company released its Q2 2017 results and revised full-year 2017 guidance, which were widely viewed as "disappointments" by the financial community. In Ap
Valeant Pharmaceuticals (NYSE:VRX) is by no means a healthy company. Investing in them is by no means for the faint of heart. Since hitting highs of $259.98 on August 4th, 2015, VRX has been a deathtrap for investors, losing 95% of its market value. There are many reasons for that decline, but I
Small cap RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) is focused on regenerative medicine - a game-changing area of medicine with the potential to fully heal damaged tissues and organs. According to Wikipedia, the term wasfirst used in a 1992 article on hospital administration by Leland Kaiser